FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Chilcott

Research Profile

Activities & Behaviors

Concepts & Ideas

Geographic Areas

Procedures

Chemicals & Drugs

Co-author Network

Publications

TOP 3
E S Everson-Hock; Elizabeth Goyder; M Johnson; R Jones; N Payne; H B Woods; James Chilcott
Community-based dietary and physical activity interventions in low socioeconomic groups in the UK: A mixed methods systematic review.
Linda Sharp; Anthony Staines; Paul Tappenden; Lesley Tilson; Cara Usher; Cathal Walsh; Sophie Whyte; Michael Barry; Alan O Ceilleachair; James Chilcott; Harry Comber
Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.
Paul Tappenden; Alan Brennan; James Chilcott; Hazel Squires; Matthew Stevenson
Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Chilcott (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: E S Everson-Hock; Elizabeth Goyder; M Johnson; R Jones; N Payne; H B Woods; James Chilcott
Community-based dietary and physical activity interventions in low socioeconomic groups in the UK: A mixed methods systematic review.
Preventive medicine 2013;56(5):265-72.
2013: Linda Sharp; Anthony Staines; Paul Tappenden; Lesley Tilson; Cara Usher; Cathal Walsh; Sophie Whyte; Michael Barry; Alan O Ceilleachair; James Chilcott; Harry Comber
Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.
BMC health services research 2013;13(1):105.
2012: Paul Tappenden; Alan Brennan; James Chilcott; Hazel Squires; Matthew Stevenson
Whole disease modeling to inform resource allocation decisions in cancer: a methodological framework.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012;15(8):1127-36.
2012: E S Everson-Hock; Elizabeth Goyder; L Guillaume; R Jones; N Payne; L M Sheppard; James Chilcott; J Clapton; A Duenas; C Swann
The effectiveness of training and support for carers and other professionals on the physical and emotional health and well-being of looked-after children and young people: a systematic review.
Child: care, health and development 2012;38(2):162-74.
2011: E S Everson-Hock; Elizabeth Goyder; L Guillaume; R Jones; N Payne; L M Sheppard; James Chilcott; J Clapton; J Cooke; A Duenas; C Swann
Supporting the transition of looked-after young people to independent living: a systematic review of interventions and adult outcomes.
Child: care, health and development 2011;37(6):767-79.
2011: R Jones; D Papaioannou; N Payne; L M Sheppard; James Chilcott; J Cooke; A Duenas; E S Everson-Hock; Elizabeth Goyder; L Guillaume; C Swann
Factors associated with outcomes for looked-after children and young people: a correlates review of the literature.
Child: care, health and development 2011;37(5):613-22.
2010: James Chilcott; Paul Tappenden; A Rawdin; M Johnson; Eva Kaltenthaler; Suzy Paisley; D Papaioannou; A Shippam
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
Health technology assessment (Winchester, England) 2010;14(25):iii-iv, ix-xii, 1-107.
2010: J Oakley; Alan Brennan; Paul Tappenden; James Chilcott
Simulation sample sizes for Monte Carlo partial EVPI calculations.
Journal of health economics 2010;29(3):468-77.
2009: Paul Tappenden; James Chilcott; Alan Brennan; Hazel Pilgrim
Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom.
International journal of technology assessment in health care 2009;25(4):470-8.
2009: James Chilcott; Myfanwy Lloyd Jones; A Wilkinson
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Health technology assessment (Winchester, England) 2009;13 Suppl 1():7-13.
2009: Abdullah Pandor; Roberta Ara; Indra Tumur; A J Wilkinson; Suzy Paisley; A Duenas; P N Durrington; James Chilcott
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials.
Journal of internal medicine 2009;265(5):568-80.
2009: E L Simpson; A Duenas; M W Holmes; D Papaioannou; James Chilcott
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation.
Health technology assessment (Winchester, England) 2009;13(17):iii, ix-x, 1-154.
2009: Mark Pickin; Cindy L Cooper; Timothy Chater; Tony O'Hagan; Keith Abrams; Nicola J Cooper; Mike Boggild; Jackie Palace; George Ebers; James Chilcott; Paul Tappenden; Jon P Nicholl
The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.
BMC neurology 2009;9():1.
2008: Roberta Ara; Abdullah Pandor; Indra Tumur; Suzy Paisley; Alejandra Duenas; Robert Williams; Anna Wilkinson; Paul Durrington; James Chilcott
Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
Clinical therapeutics 2008;30(8):1508-23.
2008: Roberta Ara; Indra Tumur; Abdullah Pandor; A Duenas; R Williams; A Wilkinson; Suzy Paisley; James Chilcott
Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.
Health technology assessment (Winchester, England) 2008;12(21):iii, xi-xiii, 1-212.
2008: S Dixon; F Faghih Nasiri; William L Ledger; E A Lenton; A Duenas; Paul Sutcliffe; James Chilcott
Cost-effectiveness analysis of different embryo transfer strategies in England.
BJOG : an international journal of obstetrics and gynaecology 2008;115(6):758-66.
2008: Allan Wailoo; Nick Bansback; James Chilcott
Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
Rheumatology (Oxford, England) 2008;47(2):119-20.
2008: Roberta Ara; Abdullah Pandor; Indra Tumur; Suzy Paisley; Alejandra Duenas; Robert Williams; Angie Rees; Anna Wilkinson; Paul Durrington; James Chilcott
Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2008;8(6):419-27.
2008: Paul H Garthwaite; James Chilcott; David J Jenkinson; Paul Tappenden
Use of expert knowledge in evaluating costs and benefits of alternative service provisions: a case study.
International journal of technology assessment in health care 2008;24(3):350-7.
2007: Alan Brennan; Samer A Kharroubi; Tony O'Hagan; James Chilcott
Calculating partial expected value of perfect information via Monte Carlo sampling algorithms.
Medical decision making : an international journal of the Society for Medical Decision Making 2007;27(4):448-70.
2007: Paul Tappenden; James Chilcott; Simon Eggington; Julietta Patnick; Hannah Sakai; Jonathan Daniel Karnon
Option appraisal of population-based colorectal cancer screening programmes in England.
Gut 2007;56(5):677-84.
2007: Paul Tappenden; John Brazier; Julie Ratcliffe; James Chilcott
A stated preference binary choice experiment to explore NICE decision making.
PharmacoEconomics 2007;25(8):685-93.
2006: Simon Eggington; Paul Tappenden; Abdullah Pandor; Suzy Paisley; M Saunders; MT Seymour; Paul Sutcliffe; James Chilcott
Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer.
British journal of cancer 2006;95(9):1195-201.
2006: Paul Tappenden; James Chilcott; Sue Ward; Simon Eggington; Daniel Hind; Silvia Hummel
Methodological issues in the economic analysis of cancer treatments.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2867-75.
2006: Yolanda Bravo Vergel; James Chilcott; Eva Kaltenthaler; Stephen Walters; Anthony Blakeborough; Steven Thomas
Economic evaluation of MR cholangiopancreatography compared to diagnostic ERCP for the investigation of biliary tree obstruction.
International journal of surgery (London, England) 2006;4(1):12-9.
2006: Abdullah Pandor; Joe Eastham; James Chilcott; Suzy Paisley; Catherine Beverley
Economics of tandem mass spectrometry screening of neonatal inherited disorders.
International journal of technology assessment in health care 2006;22(3):321-6.
2006: Eva Kaltenthaler; Stephen J Walters; James Chilcott; Anthony Blakeborough; Yolanda Bravo Vergel; Steven Thomas
MRCP compared to diagnostic ERCP for diagnosis when biliary obstruction is suspected: a systematic review.
BMC medical imaging 2006;6():9.
2006: Javier Mar; Santiago Gutiérrez-Moreno; James Chilcott
[Probabilistic cost-effectiveness analysis of the treatment of sleep apnea].
Gaceta sanitaria / S.E.S.P.A.S 2006;20(1):47-53.
2004: Emma Warren; Elaine Weatherley-Jones; James Chilcott; Catherine Beverley
Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
Health technology assessment (Winchester, England) 2004;8(45):iii, 1-57.
2004: James Chilcott; Paul Tappenden; Myfanwy Lloyd Jones; Jeremy Wight; Katie Forman; Julie Wray; Catherine Beverley
The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
BJOG : an international journal of obstetrics and gynaecology 2004;111(9):903-7.
2004: Myfanwy Lloyd Jones; Julie Wray; Jeremy Wight; James Chilcott; Katie Forman; Paul Tappenden; Catherine Beverley
A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant.
BJOG : an international journal of obstetrics and gynaecology 2004;111(9):892-902.
2004: Paul Tappenden; James Chilcott; Simon Eggington; J Oakley; Christopher Joseph McCabe
Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.
Health technology assessment (Winchester, England) 2004;8(27):iii, 1-78.
2004: Jonathan Daniel Karnon; Jean Peters; J Platt; James Chilcott; E McGoogan; Naomi Brewer
Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
Health technology assessment (Winchester, England) 2004;8(20):iii, 1-78.
2004: Michael Holmes; James Chilcott; Stephen Walters; Simon Whitby; Ron Akehurst
Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients.
Transplant international : official journal of the European Society for Organ Transplantation 2004;17(4):182-7.
2004: Carolyn J Czoski-Murray; Emma Warren; James Chilcott; Catherine Beverley; M A Psyllaki; J Cowan
Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
Health technology assessment (Winchester, England) 2004;8(13):iii, ix-x, 1-91.
2004: Eva Kaltenthaler; Yolanda Bravo Vergel; James Chilcott; Steven Thomas; T Blakeborough; Stephen J Walters; H Bouchier
A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography.
Health technology assessment (Winchester, England) 2004;8(10):iii, 1-89.
2004: Abdullah Pandor; J Eastham; Catherine Beverley; James Chilcott; Suzy Paisley
Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
Health technology assessment (Winchester, England) 2004;8(12):iii, 1-121.
2004: Matt Stevenson; J Oakley; James Chilcott
Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis.
Medical decision making : an international journal of the Society for Medical Decision Making 2004;24(1):89-100.
2003: Jonathan Daniel Karnon; Alan Brennan; James Chilcott
Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials".
The European journal of health economics : HEPAC : health economics in prevention and care 2003;4(3):239-40.
2003: Jeremy Wight; James Chilcott; Mike W Holmes; Naomi Brewer
Pulsatile machine perfusion vs. cold storage of kidneys for transplantation: a rapid and systematic review.
Clinical transplantation 2003;17(4):293-307.
2003: James Chilcott; Christopher Joseph McCabe; Paul Tappenden; Tony O'Hagan; Nicola J Cooper; Keith Abrams; Karl Claxton; David H Miller
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.
BMJ (Clinical research ed.) 2003;326(7388):522; discussion 522.
2003: James Chilcott; Alan Brennan; Andrew Booth; Jonathan Daniel Karnon; Paul Tappenden
The role of modelling in prioritising and planning clinical trials.
Health technology assessment (Winchester, England) 2003;7(23):iii, 1-125.
2003: Jeremy Wight; James Chilcott; M Holmes; Naomi Brewer
The clinical and cost-effectiveness of pulsatile machine perfusion versus cold storage of kidneys for transplantation retrieved from heart-beating and non-heart-beating donors.
Health technology assessment (Winchester, England) 2003;7(25):1-94.
2003: James Chilcott; Myfanwy Lloyd Jones; Jeremy Wight; Katie Forman; Julie Wray; Catherine Beverley; Paul Tappenden
A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative.
Health technology assessment (Winchester, England) 2003;7(4):iii-62.
2003: Stephen J Walters; Malcolm Whitfield; Ron Akehurst; James Chilcott
Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective.
PharmacoEconomics 2003;21(2):129-38.
2002: James Chilcott; Michael W Holmes; Stephen Walters; Ron Akehurst; Björn Nashan
The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.
Transplant international : official journal of the European Society for Organ Transplantation 2002;15(9-10):486-93.
2002: Eva Kaltenthaler; P Shackley; K Stevens; Catherine Beverley; Glenys Parry; James Chilcott
A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety.
Health technology assessment (Winchester, England) 2002;6(22):1-89.
2001: James Chilcott; Paul Tappenden; Myfanwy Lloyd Jones; Jeremy Wight
A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.
Clinical therapeutics 2001;23(11):1792-823; discussion 1791.
2001: Stephen J Walters; Malcolm Whitfield; Ron Akehurst; James Chilcott
Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients.
Transplantation proceedings 2001;33(7-8):3187-91.
2001: James Chilcott; S M Whitby; R Moore
Clinical impact and health economic consequences of posttransplant type 2 diabetes mellitus.
Transplantation proceedings 2001;33(5A Suppl):32S-39S.
2001: S J Cornell; James Chilcott; A Brennan
Is it feasible to plan secondary care services for coronary heart disease rationally? A quantified modelling approach for a UK Health Authority.
Journal of epidemiology and community health 2001;55(7):521-7.
2001: James Chilcott; Jeremy Wight; Myfanwy Lloyd Jones; Paul Tappenden
The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
Health technology assessment (Winchester, England) 2001;5(19):1-61.
2001: James Chilcott; M Holmes; Stephen Walters; Ron Akehurst
[Modeling long-term results of basiliximab (SIMULECT) use in patients after kidney transplantation in Great Britain].
Przegla̧d lekarski 2001;58(2):61-6.
2000: N Payne; James Chilcott; E McGoogan
Liquid-based cytology for cervical screening.
Cytopathology : official journal of the British Society for Clinical Cytology 2000;11(6):469-70.
2000: Nick Payne; James Chilcott; E McGoogan
Liquid-based cytology in cervical screening: a rapid and systematic review.
Health technology assessment (Winchester, England) 2000;4(18):1-73.